Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KER 0193

Next Previous
Drug Profile

KER 0193

Alternative Names: KER-0193

Latest Information Update: 17 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaerus Bioscience
  • Class Behavioural disorder therapies; Small molecules
  • Mechanism of Action Large conductance calcium activated potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fragile X syndrome

Most Recent Events

  • 08 Sep 2025 Servier plans a phase II trial for Fragile X syndrome in America and Europe in December 2026
  • 08 Sep 2025 Servier acquires KER 0193 from Kaerus Bioscience
  • 14 May 2025 KER 0193 receives Orphan Drug status for Fragile X syndrome in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top